A pilot study of ketamine among individuals with tobacco use disorder: tolerability and initial impact on tobacco use outcomes.
Journal of addictive diseases January 20, 2025 Janice Chuang, Riley Carpenter Lide, Nikhil Kamath et al. 3 citations
A subanesthetic dose of ketamine (0.5 mg/kg) was well tolerated in individuals with tobacco use disorder, but no significant effects were observed on cigarette smoking, craving, or withdrawal symptoms 24 hours after infusion or at an eight-day follow-up. The small pilot study randomized six participants to ketamine and four to placebo, finding only transient side effects. The results suggest that, in this limited sample, ketamine did not reduce tobacco use, though further research with different doses and routes of administration is needed to explore its potential for treating tobacco use disorder.